The board of directors of GlaxoSmithKline (GSK) has recommended 550 per cent cash dividend for the year ended December 31, 2017, said an official disclosure on Wednesday.
The final approval of the dividend will come during the annual general meeting (AGM) scheduled to be held on April 19 in Chittagong.
The record date for entitlement of dividend is on March 21.
The company has also reported earnings per share (EPS) of Tk 55.56, net asset value (NAV) per share of Tk 218.35 and net operating cash flow per share (NOCFPS) of Tk 117.74 for the year ended on December 31, 2017 as against Tk 53.51, Tk 214.65 and Tk 71.86 respectively for the same period of the previous year.
In 2016, the company also disbursed 500 per cent cash dividend.
There will be no price limit on the trading of the shares of the company today (Wednesday) following its corporate declaration.
Each share of the company, which was listed on the Dhaka bourse in 1976, closed at Tk 1580.70 on Tuesday at the Dhaka Stock Exchange (DSE).
The company’s paid-up capital is Tk 120.46 million and authorised capital is Tk 200 million, while the total number of securities is 12.04 million.
The sponsor-directors own 81.98 per cent stake in the company, while institutional investors own 16.02 per cent, foreign 0.74 per cent and general public 1.26 per cent as on January 31, 2018, the DSE data shows.
